Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 622-629

  Sirot, Eveline Jaquenoud ^a   Harenberg, Sabine ^a   Vandel, Pierre ^b   Lima, Carlos A Mendonça ^c   Perrenoud, Patrick ^d   Kemmerling, Klaus ^e   Zullino, Daniele F ^f   Hilleret, Henriette ^g   Crettol, Séverine ^h   Jonzier Perey, Michèle ^h   Golay, Kerry Powell ^h   Brocard, Muriel ^h   Eap, Chin B ^h   Baumann, Pierre ^h  

^a Psychiatrische Dienste Aargau AG   (Switzerland)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c CHAA   (Portugal)

^d Psychiatriezentrum Oberwallis ^*  (Switzerland)

^e Kantonales Spital Herisau   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g HUG   (Switzerland)

^h DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

CYP1A2; CYP2B6; CYP2D6; depression; efficacy; mirtazapine; pharmacogenetics; pharmacokinetics; smoking

Indexed keywords

CARDIOVASCULAR AGENT; CHLORAL HYDRATE; CONTRACEPTIVE AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; DRUG METABOLITE; GASTROINTESTINAL AGENT; LORAZEPAM; METOPROLOL; MINERAL; MIRTAZAPINE; PROPRANOLOL; ROFECOXIB; VITAMIN; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DSM-IV; ENANTIOMER; EVENING DOSAGE; EXCESSIVE DREAMING; FEMALE; GENOTYPE; HAMILTON SCALE; HUMAN; HYPOSALIVATION; LASSITUDE; MAJOR DEPRESSION; MALE; MEMORY DISORDER; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; STEADY STATE; SWEATING; WEIGHT GAIN;

ADULT; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; DRUG MONITORING; FEMALE; GENOTYPE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PHARMACOGENETICS; PSYCHIATRIC STATUS RATING SCALES; SEX FACTORS; SMOKING; STEREOISOMERISM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865861502     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182664d98     Document Type: Article

References (62)

1. Jaquenoud Sirot E, van der Velden JW, Rentsch K, et al. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf. 2006;29(9):735-768.
2. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37(6):243-265.
3. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104(3):173-192.
4. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442-473.
5. Hiemke C, Baumann P, Bergemann N, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in PsychiatryVupdate 2011. Pharmacopsychiatry. 2011;44(6):195-235.
6. Lane RM, Baker GB. Chirality and drugs used in psychiatry: nice to know or need to know? Cell Mol Neurobiol. 1999;19:355-372.
7. Baumann P, Zullino DF, Eap CB. Enantiomers' potential in psychopharmacologyVa critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol. 2002;12(5):433-444.
8. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427-452.
9. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol Clin Exp. 1995;10:S125YS133.
10. Hoyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 1996;93(3):184-190.
11. Davis R, Wilde MI. MirtazapineVa review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5(5):389-402.
12. de Boer T, Ruigt GSF. The selective >2-adrenoceptor antagonist mirtazapine (org 3770) enhances noradrenergic and 5-HT1AYmediated serotonergic neurotransmission. CNS Drugs. 1995;4(Suppl 1):29-38.
13. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol. 1995;10(Suppl 4):11-17.
14. Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006;21(2):117-125.
15. Bengtsson HJ, Kele J, Johansson J, et al. Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(4-5):406-412.
16. Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull. 2004;63(3):237-241.
17. Haddjeri N, Blier P, de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther. 1996;277:861-871.
18. McGrath C, Burrows GD, Norman TR. Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur J Pharmacol. 1998;356:121-126.
19. Brockmö ller J, Meineke I, Kirchheiner J. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther. 2007;81(5):699-707.
20. de Graaf JS, Delbressine LPC. Contributions of the enantiomers of mirtazapine (ORG 3770) and of its demethyl metabolite to its neuropharmacological profile in rats. Eur J Pharmacol. 1990;183(2):583-584.
21. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38(6):461-474.
22. Timmer CJ, Paanakker JE, Van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Hum Psychopharmacol Clin Exp. 1996;11:497-509.
23. Shams M, Hiemke C, Hartter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit. 2004;26(1):78-84.
24. Reis M, Prochazka J, Sitsen A, et al. Inter-and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit. 2005;27(4):469-477.
25. Lind AB, Reis M, Bengtsson F, et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet. 2009;48(1):63-70.
26. Stö rmer E, Von Moltke LL, Shader RI, et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000;28:1168-1175.
27. Dodd S, Boulton DW, Burrows GD, et al. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum Psychopharmacol Clin Exp. 2001;16:541-544.
28. Dahl ML, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest. 1997;13:37-46.
29. Delbressine LPC, Moonen MEG, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest. 1998;15:45-55.
30. Baumann P, Jonzier-Perey M, Paus E, et al. Mirtazapine enantiomers in blood and cerebrospinal fluid. Neuropsychobiology. 2006;54(3):179-181.
31. Grasmader K, Verwohlt PL, Kuhn KU, et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004;60(7):473-480.
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
33. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
34. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
35. Paus E, Jonzier-Perey M, Cochard N, et al. Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Ther Drug Monit. 2004;26(4):366-374.
36. Baumann P, Meyer JW, Amey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit. 1992;14:1-8.
37. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80(6):668-681.
38. Grohmann R, Engel RR, Ruther E, et al. The AMSP drug safety program: methods and global results. Pharmacopsychiatry. 2004;37(Suppl 1):S4YS11.
39. Knezevic B, Stephan PL, Grohmann R, et al. Das Antipsychotika-assoziierte metabolische Syndrom. Psychopharmakotherapie. 2005;12(6):235-238.
40. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry. 2008;69(9):1404-1415.
41. Kasper S, Montgomery SA, Möller HJ, et al. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. World J Biol Psychiatry. 2010;11(1):36-44.
42. Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4 and CYP3A5 genotyped subjects. Eur J Clin Pharmacol. 2004;60(4):231-236.
43. Sachse C, Brockmöller J, Bauer S, et al. Functional significance of a CY9A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47(4):445-449.
44. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4¶-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9(5):539-549.
45. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003;35(2-3):99-106.
46. Rebsamen MC, Desmeules J, Daali Y, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009;9(1):34-41.
47. Allorge D, Harlow J, Boulet O, et al. In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics. 2001;11(8):739-741.
48. Vistisen K, Loft S, Poulsen HE. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. Adv Exp Med Biol. 1991;283:407-411.
49. Kohler D, Hartter S, Fuchs K, et al. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics. 1997;7(6):453-461.
50. Rowland K, Yeo WW, Ellis SW, et al. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. Br J Clin Pharmacol. 1994;38(1):9-14.
51. Bachmann K, White D, Jauregui L, et al. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol. 2003;43(10):1082-1090.
52. Backman JT, Karjalainen MJ, Neuvonen M, et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 2006;62(3):345-357.
53. Kirchheiner J, Henckel HB, Meineke I, et al. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004;24(6):647-652.
54. Eap CB, Bender S, Jaquenoud Sirot E, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004;24(2):214-219.
55. Dobrinas M, Cornuz J, Oneda B, et al. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther. 2011;90(1):117-125.
56. Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;13(10):619-626.
57. Greenblatt DJ, Von Moltke LL, Harmatz JS, et al. Human cytochromes mediating sertraline biotransformation: seeking attribution. J Clin Psychopharmacol. 1999;19(6):489-493.
58. Baumann P, Barbe R, Vabre-Bogdalova A, et al. Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. J Clin Psychopharmacol. 2006;26(6):679-681.
59. Thorn CF, Lamba JK, Lamba V, et al. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics. 2010;20(8):520-523.
60. Grasmäder K, Verwohlt PL, Kuhn KU, et al. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry. 2005;38(3):113-117.
61. Hedlund E, Gustafsson JA, Warner M. Cytochrome P450 in the brain: 2B or not 2B. Trends Pharmacol Sci. 1998;19(3):82-85.
62. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos. 1997;25(12):1379-1382.